Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
SETBP1 mutant N/A myelodysplastic/myeloproliferative neoplasm not applicable detail...
PDGFRA rearrange Imatinib myelodysplastic/myeloproliferative neoplasm sensitive detail...
KRAS G12D Pictilisib myelodysplastic/myeloproliferative neoplasm sensitive detail...
ASXL1 inact mut N/A myelodysplastic/myeloproliferative neoplasm not applicable detail...
CBL mutant N/A myelodysplastic/myeloproliferative neoplasm not applicable detail...
ASXL1 wild-type TET2 mutant Azacitidine myelodysplastic/myeloproliferative neoplasm sensitive detail...
ASXL1 wild-type TET2 mutant Decitabine myelodysplastic/myeloproliferative neoplasm sensitive detail...
Unknown unknown Ruxolitinib myelodysplastic/myeloproliferative neoplasm not applicable detail...
EZH2 mutant N/A myelodysplastic/myeloproliferative neoplasm not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00946647 Phase II Panobinostat Azacitidine A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Active, not recruiting
NCT01164163 Phase I Ruxolitinib INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Recruiting
NCT01822509 Phase I Nivolumab + Ipilimumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated
NCT02089230 Phase Ib/II Binimetinib Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Active, not recruiting
NCT02143635 Phase I HDM201 Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Active, not recruiting
NCT02158858 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms Recruiting
NCT02530476 Phase Ib/II Selinexor + Sorafenib Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Active, not recruiting
NCT02564536 Phase I Pacritinib + Decitabine Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Recruiting
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Recruiting
NCT02807272 Phase II Tipifarnib Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML) Recruiting
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn
NCT02907359 Phase III Cytarabine Guadecitabine Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting
NCT02935361 Phase Ib/II Atezolizumab + Guadecitabine Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Recruiting
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Recruiting
NCT03075826 Phase II Guadecitabine A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Recruiting
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting
NCT03238248 Phase II Azacitidine + MLN4924 Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Recruiting
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Recruiting
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting
NCT03397173 Azacitidine TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid Recruiting